Harm Reduction: Evidence-Based Approaches to Reducing Drug-Related Harm

Introduction

Harm reduction is a public health approach that aims to reduce the negative consequences of drug use without requiring abstinence. Rather than focusing exclusively on stopping drug use, harm reduction meets people where they are — providing practical tools and services that reduce the immediate harms of drug use while maintaining engagement with people who may not yet be ready for or able to achieve abstinence. Harm reduction is not a substitute for treatment — it is a complement to it, and often a pathway into treatment.

The evidence base for harm reduction is strong. Harm reduction interventions have been shown to reduce overdose deaths, HIV and hepatitis C transmission, emergency department visits, and criminal justice involvement, while improving engagement with treatment and recovery services. Despite this evidence, harm reduction remains controversial in some communities, often due to the misconception that it "enables" drug use.

Key Definitions

Harm reduction: Policies, programs, and practices that aim to reduce the negative health, social, and economic impacts of drug use without requiring abstinence.

Syringe service programs (SSPs): Programs that provide sterile syringes and other injection equipment to people who inject drugs, reducing HIV and hepatitis C transmission.

Supervised consumption sites (SCS): Facilities where people can use pre-obtained drugs under medical supervision, with immediate access to naloxone and other emergency care.

Low-threshold services: Services that minimize barriers to access — no requirement for abstinence, sobriety, or treatment engagement. Essential for reaching people who are not yet ready for traditional treatment.

Continuum of care: A range of services from harm reduction to treatment to recovery support, designed to meet people at different stages of their relationship with substances.

Core Harm Reduction Interventions

Naloxone distribution: Distributing naloxone to people who use drugs, their families, and community members is one of the most evidence-based harm reduction interventions. Multiple studies have shown that community naloxone distribution programs significantly reduce overdose mortality. The CDC estimates that community naloxone programs have reversed over 26,000 overdoses.

Syringe service programs (SSPs): SSPs provide sterile syringes and other injection equipment to people who inject drugs, dramatically reducing HIV and hepatitis C transmission. The CDC and other major health organizations strongly support SSPs based on extensive evidence:

• SSPs reduce HIV transmission by 50% among people who inject drugs.
• SSPs reduce hepatitis C transmission by 50-80%.
• SSPs do not increase drug use in communities where they operate.
• SSPs are cost-effective — the cost of preventing one HIV infection through SSPs is far less than the lifetime cost of HIV treatment.
• SSPs serve as a gateway to treatment — people who use SSPs are 5 times more likely to enter treatment than those who do not.

Fentanyl test strips: Fentanyl test strips allow people to test their drugs for fentanyl before use, enabling informed decision-making. Research has shown that people who test positive for fentanyl are more likely to use less, use with others, or not use at all. Fentanyl test strips are now legal in most states.

Drug checking services: Beyond fentanyl test strips, more comprehensive drug checking services — using mass spectrometry or other analytical methods — can identify the full composition of drug samples, including adulterants and contaminants. These services are available in some harm reduction programs and are increasingly recognized as an important tool for reducing overdose risk.

Supervised consumption sites (SCS): SCS are facilities where people can use pre-obtained drugs under medical supervision. They provide immediate access to naloxone and other emergency care, and connect people with treatment and social services. Evidence from over 100 SCS operating in Europe, Canada, and Australia shows:

• No overdose deaths have occurred inside SCS.
• SCS reduce overdose deaths in surrounding communities.
• SCS reduce emergency department visits and ambulance calls.
• SCS do not increase drug use or crime in surrounding communities.
• SCS connect people with treatment — many people who use SCS subsequently enter treatment.

The first legally sanctioned SCS in the United States opened in New York City in 2021 and have prevented hundreds of overdose deaths.

Medication-assisted treatment as harm reduction: MAT — buprenorphine, methadone, and naltrexone — can be understood as harm reduction as well as treatment. Even for people who continue to use some substances, MAT reduces overdose risk, HIV transmission, and criminal activity. Low-threshold MAT programs — which provide MAT without requiring abstinence from all substances — are an important harm reduction approach.

The Evidence Against "Enabling"

A common objection to harm reduction is that it "enables" drug use by removing consequences. The evidence does not support this concern:

• SSPs do not increase drug use in communities where they operate.
• SCS do not increase drug use or crime in surrounding communities.
• Naloxone distribution does not increase opioid use.
• Harm reduction programs serve as gateways to treatment — people who use harm reduction services are more likely to enter treatment than those who do not.

The "enabling" concern reflects a moral model of addiction — the view that consequences are necessary to motivate change. The evidence from addiction neuroscience and public health research does not support this model. Reducing harm while maintaining engagement is more effective than allowing harm to accumulate in the hope that it will motivate change.

Harm Reduction and Recovery

Harm reduction and recovery are not opposites — they are complementary. Harm reduction keeps people alive and connected to services until they are ready for recovery. Many people who are now in long-term recovery first engaged with the healthcare system through harm reduction services. The goal of harm reduction is not to keep people using drugs indefinitely — it is to reduce harm while maintaining engagement and supporting movement toward recovery when the person is ready.

Frequently Asked Questions

Does harm reduction enable drug use?
No. Research consistently shows that harm reduction interventions do not increase drug use. They reduce harm while maintaining engagement with people who may not yet be ready for abstinence-based treatment. Harm reduction programs often serve as gateways to treatment.

Is harm reduction compatible with 12-step recovery?
Many people in 12-step recovery support harm reduction as a public health approach, even if they personally pursue abstinence. The goal of keeping people alive until they are ready for recovery is consistent with the values of most recovery communities. However, some 12-step communities have concerns about harm reduction — this is an area of ongoing dialogue.

Where can I find harm reduction services?
Harm reduction services can be found through SAMHSA's treatment locator, the North American Syringe Exchange Network (NASEN), and local health departments. Many harm reduction organizations also provide naloxone by mail.

Key Takeaways

• Harm reduction reduces the negative consequences of drug use without requiring abstinence, and is complementary to — not a substitute for — treatment.
• Evidence-based harm reduction interventions include naloxone distribution, syringe service programs, fentanyl test strips, and supervised consumption sites.
• Harm reduction does not increase drug use — research consistently shows that it reduces harm while maintaining engagement.
• Harm reduction programs often serve as gateways to treatment, connecting people with services when they are ready.
• Harm reduction and recovery are complementary — harm reduction keeps people alive until they are ready for recovery.

Additional Resources

Related articles on Sobriety Navigator: Opioid Overdose Prevention, Fentanyl and the Opioid Crisis, Medication-Assisted Treatment, Stages of Recovery.